m6A-centered Drug Response Information

General Information of the Drug (ID: M6ADRUG0079)
Name
Pembrolizumab
Status Approved [1]
TTD Drug ID
D08ANZ
DrugBank ID
DB09037
Full List of m6A Targets Related to This Drug
Putative heat shock 70 kDa protein 7 (HSPA7)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary Putative heat shock 70 kDa protein 7 (HSPA7) promoted macrophage infiltration and SPP1 expression via upregulating the YAP1 and LOX expression of glioblastoma stem cells in vitro and in clinical glioblastoma tumor samples. HSPA7 is expected to predict the ability of PD-1 inhibitors to respond to treatment in glioblastoma.
Responsed Disease Glioblastoma ICD-11: 2A00.00
 Disease Info 
Pathway Response PD-L1 expression and PD-1 checkpoint pathway in cancer hsa05235
In-vitro Model A-172 Glioblastoma Homo sapiens CVCL_0131
GSC 20 (Mesenchymal (MES) subtype GSC cell lines)
GSC 20 (Mesenchymal (MES) subtype GSC cell lines)
GSC 8-11 (Proneural (PN) subtype GSC cell lines)
LN-229 Glioblastoma Homo sapiens CVCL_0393
Neural progenitor cells (NPCs) (The progenitor cells of the CNS)
U-251MG Astrocytoma Homo sapiens CVCL_0021
U-87MG ATCC Glioblastoma Homo sapiens CVCL_0022
References
Ref 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 2 The N(6)-Methyladenosine-Modified Pseudogene HSPA7 Correlates With the Tumor Microenvironment and Predicts the Response to Immune Checkpoint Therapy in Glioblastoma. Front Immunol. 2021 Jul 20;12:653711. doi: 10.3389/fimmu.2021.653711. eCollection 2021.